Related Experiment Video
Updated: Apr 4, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Synthesis and structural characterisation of bismuth(III) hydroxamates and their activity against Helicobacter pylori
Amita Pathak1, Victoria L Blair, Richard L Ferrero
1School of Chemistry, Monash University, Clayton, Melbourne, VIC 3800, Australia.
Abstract:
Seven new bismuth(iii) hydroxamate complexes derived from the hydroxamic acids N-methylfurohydroxamic acid (H-MFHA), N-benzoyl-N-phenylhydroxamic acid (H-BPHA), salicylhydroxamic acid (H2-SHA), benzohydroxamic acid (H2-BHA), and acetohydroxamic acid (H2-AHA) have been synthesized and characterized. The complexes formed are either tris-hydroxamato complexes containing only mono-anionic ligands, [Bi(H-SHA)3], [Bi(MFHA)3] and [Bi(BPHA)3]; mixed-anion complexes, [Bi(SHA)(H-SHA)] and [Bi(AHA)(H-AHA)]; and potassium bismuthate complexes, K[Bi(SHA)2] and K[Bi(BHA)2]. The solid-state structure of three complexes has been determined through single crystal X-ray diffraction; [Bi(MFHA)3]2·Me2C[double bond, length as m-dash]O, {[Bi(SHA)(H-SHA)(DMSO)2][Bi(SHA)(H-SHA)(DMSO)]·DMSO}∞ and [Bi(BPHA)3]2·2EtOH. All the complexes and their parent acids were assessed for the bactericidal activity against three strains of Helicobacter pylori (26695, B128 and 251). Of the acids, only acetohydroxamic acid showed any activity at low concentrations (MIC 6.25 μg mL(-1); 83.26 μM) while the others were not toxic below 25 μg mL(-1). In contrast, their bismuth(iii) complexes all showed excellent activity across all three strains (e.g. 0.28 μM for [Bi(H-SHA)3] to 6.01 μM for K[Bi(BHA)2] against strain 251) with only minor variations in activity being both ligand and composition dependant.
More Related Videos
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Composition of Polyprotic Acid Solutions as a Function of pH
A graph with the alpha values is plotted against the volume of...

